SG10202006688RA - Bicyclic compounds for diagnosis and therapy - Google Patents
Bicyclic compounds for diagnosis and therapyInfo
- Publication number
- SG10202006688RA SG10202006688RA SG10202006688RA SG10202006688RA SG10202006688RA SG 10202006688R A SG10202006688R A SG 10202006688RA SG 10202006688R A SG10202006688R A SG 10202006688RA SG 10202006688R A SG10202006688R A SG 10202006688RA SG 10202006688R A SG10202006688R A SG 10202006688RA
- Authority
- SG
- Singapore
- Prior art keywords
- diagnosis
- therapy
- bicyclic compounds
- bicyclic
- compounds
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16159878 | 2016-03-11 | ||
EP16199577 | 2016-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202006688RA true SG10202006688RA (en) | 2020-08-28 |
Family
ID=58488956
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006688RA SG10202006688RA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
SG11201807778YA SG11201807778YA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807778YA SG11201807778YA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
Country Status (14)
Country | Link |
---|---|
US (3) | US20190071450A1 (en) |
EP (2) | EP4001277A3 (en) |
JP (4) | JP2019512491A (en) |
KR (3) | KR102464274B1 (en) |
CN (2) | CN109071528B (en) |
AU (1) | AU2017231781C1 (en) |
BR (1) | BR112018068066B1 (en) |
CA (2) | CA3224365A1 (en) |
ES (1) | ES2905539T3 (en) |
MX (1) | MX2018010693A (en) |
NZ (1) | NZ746901A (en) |
RU (2) | RU2766139C2 (en) |
SG (2) | SG10202006688RA (en) |
WO (1) | WO2017153601A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210252175A1 (en) * | 2018-06-08 | 2021-08-19 | Ac Immune Sa | Novel compounds for diagnosis |
MX2020014315A (en) * | 2018-06-27 | 2021-05-27 | Ptc Therapeutics Inc | Heteroaryl compounds for treating huntington's disease. |
CN112912376A (en) * | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases |
WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
US20210002712A1 (en) * | 2019-07-05 | 2021-01-07 | National University Corporation Chiba University | Phosphatidic acid sensor |
GB201914989D0 (en) * | 2019-10-16 | 2019-11-27 | Karin & Sten Mortstedt Cbd Solutions Ab | Selective ligands for TAU Aggregates |
JP2023502794A (en) * | 2019-11-19 | 2023-01-25 | モダグ ゲーエムベーハー | Novel compounds for the diagnosis, treatment and prevention of diseases associated with α-synuclein aggregation |
WO2021204589A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
AU2021267006A1 (en) | 2020-05-07 | 2022-11-10 | Ac Immune Sa | Novel compounds for diagnosis |
AR123730A1 (en) * | 2020-10-15 | 2023-01-04 | Ac Immune Sa | NOVEL COMPOUNDS |
CN117940435A (en) * | 2021-07-16 | 2024-04-26 | Ac免疫有限公司 | Novel compounds for diagnosing TDP-43 proteinopathies |
TW202328150A (en) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
TW202328151A (en) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | Substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines, salts thereof and their use as herbicidally active substances |
CA3237543A1 (en) | 2021-11-10 | 2023-05-19 | Jerome Molette | Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis |
CA3235230A1 (en) | 2021-11-10 | 2023-05-19 | Jerome Molette | 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis |
WO2023083961A1 (en) | 2021-11-10 | 2023-05-19 | Ac Immune Sa | Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis |
CN116262744A (en) * | 2021-12-13 | 2023-06-16 | 复旦大学 | Small molecule probes for alpha-synuclein aggregate imaging |
WO2023163033A1 (en) * | 2022-02-24 | 2023-08-31 | 国立研究開発法人量子科学技術研究開発機構 | NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF |
WO2024059845A1 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Supramolecular polymer therapeutics and diagnostics |
WO2024068948A1 (en) * | 2022-09-30 | 2024-04-04 | Ac Immune Sa | Novel compounds for the diagnosis of tdp-43 proteinopathies |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05125076A (en) * | 1991-11-06 | 1993-05-21 | Canon Inc | Liquid-crystalline compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using the same |
CZ20001709A3 (en) * | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Thienopyrimide and thienopyridine derivatives, pharmaceutical compositions and treatment methods based thereon |
DK1334091T3 (en) * | 2000-08-24 | 2012-10-15 | Univ Pittsburgh | Thioflavin derivatives and their use in the diagnosis and therapy of Alzheimer's disease |
US6700722B2 (en) * | 2001-05-25 | 2004-03-02 | Infineon Technologies Ag | High-speed zero phase restart of a multiphase clock |
WO2003045929A1 (en) * | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
WO2006066174A1 (en) * | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
AR056200A1 (en) * | 2005-09-27 | 2007-09-26 | Wyeth Corp | TIENO [2,3-B] PIRIDIN-5-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE |
AU2007229492B2 (en) * | 2006-03-28 | 2011-11-03 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
EP2023919A4 (en) * | 2006-05-08 | 2010-12-22 | Molecular Neuroimaging Llc | Compounds and amyloid probes thereof for therapeutic and imaging uses |
EA015500B9 (en) * | 2006-06-08 | 2012-03-30 | Эли Лилли Энд Компани | Novel mch receptor antagonists |
ES2587014T3 (en) * | 2006-11-24 | 2016-10-20 | Ac Immune S.A. | N- (methyl) -pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid proteins |
CA2686754C (en) * | 2007-05-11 | 2014-10-28 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
JP2011511005A (en) * | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 2-aminopyridine kinase inhibitor |
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
WO2009126635A1 (en) * | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
JP2011524864A (en) | 2008-05-30 | 2011-09-08 | メルク・シャープ・エンド・ドーム・コーポレイション | Novel substituted azabenzoxazole |
EP2323697A2 (en) * | 2008-07-24 | 2011-05-25 | Siemens Medical Solutions USA, Inc. | Imaging agents useful for identifying ad pathology |
WO2010021381A1 (en) * | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | Fused heterocyclic derivative and use thereof |
GB0821994D0 (en) | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
WO2011119869A1 (en) * | 2010-03-24 | 2011-09-29 | Medical University Of South Carolina | Compositions and methods for the treatment of degenerative diseases |
DK2558446T5 (en) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | New compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
EP2377860A1 (en) * | 2010-04-16 | 2011-10-19 | AC Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
GB201012889D0 (en) * | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
WO2012007510A1 (en) * | 2010-07-14 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Compounds for binding and imaging amyloid plaques and their use |
DE102010045797A1 (en) | 2010-09-20 | 2012-03-22 | Klinikum Darmstadt Gmbh | Compounds for the diagnosis of neurodegenerative diseases of the olfactory epithelium |
JP5720253B2 (en) * | 2011-01-06 | 2015-05-20 | コニカミノルタ株式会社 | ORGANIC ELECTRONIC ELECTRONIC DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE HAVING THE SAME |
EP2560008B1 (en) | 2011-08-18 | 2016-11-30 | Korea Institute of Science and Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
US9464064B2 (en) * | 2011-09-07 | 2016-10-11 | University Of Kansas | HCV helicase inhibitors and methods of use thereof |
JP6371219B2 (en) * | 2011-09-19 | 2018-08-08 | シー2エヌ ダイアグノスティクス | Methods for diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and related processes |
CA2853633A1 (en) * | 2011-10-27 | 2013-05-02 | Proteotech Inc | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
WO2013156431A1 (en) * | 2012-04-17 | 2013-10-24 | Syngenta Participations Ag | Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives |
KR20150022876A (en) * | 2012-06-22 | 2015-03-04 | 이 아이 듀폰 디 네모아 앤드 캄파니 | Fungicidal heterocyclic compounds |
WO2014113191A1 (en) * | 2013-01-15 | 2014-07-24 | Xiaohu Zhang | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
TWI652014B (en) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | Heterocyclic substituted bicycloazole insecticide |
WO2015091584A1 (en) * | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
DK3186233T3 (en) | 2014-08-29 | 2021-11-22 | Chdi Foundation Inc | PROBS FOR IMAGINATION OF HUNTINGTIN PROTEIN |
ES2691246T3 (en) | 2014-12-02 | 2018-11-26 | Bayer Cropscience Ag | Bicyclic compounds such as pesticides |
US10793582B2 (en) | 2015-10-22 | 2020-10-06 | Mitsubishi Tanabe Pharma Corporation | Bicyclic heterocyclic compound |
-
2017
- 2017-03-10 BR BR112018068066-4A patent/BR112018068066B1/en active IP Right Grant
- 2017-03-10 CA CA3224365A patent/CA3224365A1/en active Pending
- 2017-03-10 CN CN201780016194.6A patent/CN109071528B/en active Active
- 2017-03-10 SG SG10202006688RA patent/SG10202006688RA/en unknown
- 2017-03-10 AU AU2017231781A patent/AU2017231781C1/en active Active
- 2017-03-10 WO PCT/EP2017/055754 patent/WO2017153601A1/en active Application Filing
- 2017-03-10 RU RU2018135709A patent/RU2766139C2/en active
- 2017-03-10 KR KR1020187029373A patent/KR102464274B1/en active IP Right Grant
- 2017-03-10 MX MX2018010693A patent/MX2018010693A/en unknown
- 2017-03-10 KR KR1020227038417A patent/KR102646115B1/en active IP Right Grant
- 2017-03-10 US US16/084,223 patent/US20190071450A1/en not_active Abandoned
- 2017-03-10 ES ES17715405T patent/ES2905539T3/en active Active
- 2017-03-10 EP EP21214388.7A patent/EP4001277A3/en active Pending
- 2017-03-10 JP JP2018548003A patent/JP2019512491A/en active Pending
- 2017-03-10 NZ NZ746901A patent/NZ746901A/en unknown
- 2017-03-10 SG SG11201807778YA patent/SG11201807778YA/en unknown
- 2017-03-10 KR KR1020247007479A patent/KR20240036709A/en active Application Filing
- 2017-03-10 EP EP17715405.1A patent/EP3426653B1/en active Active
- 2017-03-10 RU RU2022101103A patent/RU2022101103A/en unknown
- 2017-03-10 CA CA3015947A patent/CA3015947A1/en active Pending
- 2017-03-10 CN CN202310122299.7A patent/CN116199700A/en active Pending
-
2020
- 2020-06-05 US US16/894,682 patent/US11623931B2/en active Active
-
2021
- 2021-06-07 JP JP2021095111A patent/JP7297323B2/en active Active
- 2021-08-25 JP JP2021137179A patent/JP7383304B2/en active Active
-
2023
- 2023-02-27 US US18/114,654 patent/US20240051967A1/en active Pending
- 2023-06-26 JP JP2023104451A patent/JP2023116823A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202006688RA (en) | Bicyclic compounds for diagnosis and therapy | |
IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
HK1248773A1 (en) | Therapeutic and diagnostic methods for cancer | |
HK1250376A1 (en) | Therapeutic and diagnostic methods for cancer | |
IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
HK1244802A1 (en) | Fused bicyclic compounds for the treatment of disease | |
HK1245795A1 (en) | Fused bicyclic compounds for the treatment of disease | |
IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
PL3191182T3 (en) | Apparatus for providing hyperthermia therapy | |
HK1258128A1 (en) | Selection of patients for combination therapy | |
HK1258727A1 (en) | Therapeutic compounds | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
HK1249756A1 (en) | Fused bicyclic compounds for the treatment of disease | |
GB201608797D0 (en) | Therapeutic use | |
PL3129483T3 (en) | Combination therapy for the treatment of autoimmune diseases | |
ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
GB201617339D0 (en) | Therapeutic compounds | |
GB201616839D0 (en) | Therapeutic compounds | |
IL263821A (en) | Therapeutic compounds | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
ZA201704589B (en) | Compounds for the treatment of cancer | |
GB201609790D0 (en) | Therapeutic compounds | |
GB201609737D0 (en) | Therapeutic compounds | |
GB201501202D0 (en) | Novel methods for diagnosis and therapy |